Suppr超能文献

基于胎儿-母体微嵌合体的非T细胞去除的HLA单倍型相合干细胞移植治疗晚期血液系统恶性肿瘤

Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism.

作者信息

Shimazaki Chihiro, Ochiai Naoya, Uchida Ryo, Okano Akira, Fuchida Shin-ichi, Ashihara Eishi, Inaba Tohru, Fujita Naohisa, Maruya Etsuko, Nakagawa Masao

机构信息

Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

出版信息

Blood. 2003 Apr 15;101(8):3334-6. doi: 10.1182/blood-2002-09-2883. Epub 2002 Dec 12.

Abstract

Feto-maternal microchimerism suggests that immunologic tolerance exists between mother and fetus. Based on this hypothesis, we performed haploidentical stem cell transplantation (SCT) without T-cell depletion (TCD) in 5 patients with advanced hematologic malignancies. HLA incompatibilities for graft-versus-host disease (GVHD) direction included 3-loci mismatches in 4 patients, and 2-loci mismatches in one patient. Recipient chimeric cells were detected in all patients. The prophylaxis against GVHD was tacrolimus with minidose methotrexate. Engraftment was obtained in all patients. An acute GVHD of less than or equal to grade 2 developed in all patients except one who developed tacrolimus encephalopathy. Two patients died, 1 from fungal pneumonia and 1 from disease progression. The other 3 patients survived, with one patient in complete remission. These observations suggest that haploidentical SCT based on the feto-maternal microchimerism without TCD is possible.

摘要

母胎微嵌合体表明母亲与胎儿之间存在免疫耐受。基于这一假设,我们对5例晚期血液系统恶性肿瘤患者进行了未进行T细胞清除(TCD)的单倍体干细胞移植(SCT)。移植物抗宿主病(GVHD)方向的HLA不相容性包括4例患者为3位点错配,1例患者为2位点错配。所有患者均检测到受者嵌合细胞。预防GVHD采用他克莫司联合小剂量甲氨蝶呤。所有患者均实现植入。除1例发生他克莫司脑病的患者外,所有患者均发生了≤2级的急性GVHD。2例患者死亡,1例死于真菌性肺炎,1例死于疾病进展。其他3例患者存活,其中1例完全缓解。这些观察结果表明,基于母胎微嵌合体且未进行TCD的单倍体SCT是可行的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验